This question is phrased perfectly: the important consideration is whether sequential therapy would be just as good, i.e. the "old" standard of care. Unfortunately, this is not how the three trials cited above were designed. Control-arm HRRm patients were assumed to have access to PARPi post-pr...

In my opinion, there is sufficient evidence. There is strong and consistent improvement in PFS across all trials for patients with BRCA genomic alterations. For patients with other alterations, such as PALB2 or RAD51, there is less data given fewer patients. Finally, the data suggests less effect fo...

Absolutely, three very well conducted trials: PROPEL, MAGNITUDE, and TALAPRO-2 have now enriched our treatment armamentarium.